CERVOMED INC. - COMMON

9,8000

17-апреля-25 16:45:00

15 мин. задержка

Акции

+0,3100

+3,27%

Сегодняшний диапазон

9,6000 - 10,4000

ISIN

N/A

Источник

NASDAQ

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

02 апр 2025 07:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

25 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

17 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

10 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed to Present at the 8th International Lewy Body Dementia Conference

29 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

10 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

27 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Key Senior Leadership Appointments

13 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

12 ноя 2024 07:00:01 Источник Nasdaq GlobeNewswire
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08 ноя 2024 09:55:32 Источник Nasdaq GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences

07 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences

27 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.